Prader—Willi syndrome and the hypothalamus

Dysfunction of various hypothalamic systems may be the basis of a number of symptoms in Prader—Willi syndrome. The often abnormal position of the baby in the uterus at the onset of labour, the high percentage of infants with asphyxia and the high proportion of children born prematurely or post‐maturely may all be related to abnormal fetal hypothalamic systems, as the fetal hypothalamus plays a crucial role in labour. Abnormal luteinizing hormone‐releasing hormone neurones are thought to be responsible for the decreased levels of sex hormones, resulting in non‐descended testes, undersized sex organs and insufficient growth during puberty. A lack of growth hormone‐releasing hormone may also contribute to the short stature of patients with Prader—Willi syndrome. In addition, the aberrant control of body temperature and daytime hypersomnolence may result from hypothalamic disturbances. The number of oxytocin neurones – the putative satiety neurones – in the hypothalamic paraventricular nucleus is markedly decreased in Prader—Willi syndrome. This is presumed to be the basis of the insatiable hunger and obesity of patients with the syndrome. □ Growth hormone, growth hormone‐releasing hormone, hypothalamus, insatiable hunger, obesity, oxytocin, perinatal problems, Prader—Willi syndrome

[1]  B. Bloch,et al.  Comparative immunohistochemical study of the distribution of neuropeptide Y, growth hormone-releasing factor and the carboxyterminus of precursor protein GHRF in the human hypothalamic infundibular area. , 1990, Neuroendocrinology.

[2]  S. Leibowitz,et al.  Hypothalamic paraventricular nucleus lesions produce overeating and obesity in the rat , 1981, Physiology & Behavior.

[3]  D. Swaab,et al.  THE INFLUENCE OF ANENCEPHALY UPON INTRAUTERINE GROWTH OF FETUS AND PLACENTA AND UPON GESTATION LENGTH , 1973, The Journal of obstetrics and gynaecology of the British Commonwealth.

[4]  R. Wharton,et al.  NEONATAL RESPIRATORY DEPRESSION AND DELAY IN DIAGNOSIS IN PRADER‐WILLI SYNDROME , 1989, Developmental medicine and child neurology.

[5]  R. Scully,et al.  Hypogonadotropinism in Prader-Willi syndrome. Induction of puberty and sperm altogenesis by clomiphene citrate. , 1972, The American journal of medicine.

[6]  D. Swaab,et al.  Circulating neurohypophyseal hormones in anencephalic infants. , 1987, American journal of obstetrics and gynecology.

[7]  D. Swaab,et al.  Vasopressin and oxytocin: distribution and putative functions in the brain. , 1983, Progress in brain research.

[8]  D. Swaab,et al.  The influence of the fetal hypothalamus and pituitary on the onset and course of parturition. , 1977, Ciba Foundation symposium.

[9]  E. Ghigo,et al.  Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome. , 1993, Hormone research.

[10]  R. Ruvalcaba,et al.  Hypogonadism in Prader-Willi syndrome. , 1975, American journal of mental deficiency.

[11]  J. Parkes,et al.  Sleep apnoea in the Prader‐Willi syndrome , 1994, Journal of sleep research.

[12]  A. Prader Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach myatonieartigem Zustand im Neugeborenenalter. , 1956 .

[13]  E. Stricker,et al.  Brain oxytocin receptor antagonism blunts the effects of anorexigenic treatments in rats: evidence for central oxytocin inhibition of food intake. , 1991, Endocrinology.

[14]  P. Fredrickson,et al.  Sleep and breathing in patients with the Prader-Willi syndrome. , 1991, Mayo Clinic proceedings.

[15]  M. Sarrantonio,et al.  Growth Hormone Secretion and Effects of Growth Hormone Therapy on Growth Velocity and Weight Gain in Children with Prader-Willi Syndrome , 1996, Journal of pediatric endocrinology & metabolism : JPEM.

[16]  V. A. Holm,et al.  Growth Hormone Secretion in Prader‐Willi Syndrome , 1990, Acta paediatrica Scandinavica.

[17]  D. Swaab,et al.  Differential expression of the neuroendocrine polypeptide 7B2 in hypothalami of Prader-(Labhart)-Willi syndrome patients , 1994, Brain Research.

[18]  D. Swaab,et al.  Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. , 1995, The Journal of clinical endocrinology and metabolism.

[19]  E. Stricker,et al.  Oxytocin and an oxytocin agonist administered centrally decrease food intake in rats , 1991, Peptides.

[20]  M. Castro-Magana,,et al.  Pituitary Evaluation and Growth Hormone Treatment in Prader-Willi Syndrome , 1991 .

[21]  A. Kales,et al.  Sleep in the Prader-Willi syndrome. Clinical and polygraphic findings. , 1984, Archives of neurology.

[22]  A. Benelli,et al.  Oxytocin-induced inhibition of feeding and drinking: No sexual dimorphism in rats , 1991, Neuropeptides.

[23]  D. Swaab,et al.  Life span changes in the presence of alpha-melanocyte-stimulating-hormone-containing cells in the human pituitary. , 1979, Journal of developmental physiology.

[24]  Darrell M. Wilson,et al.  Growth hormone treatment of short stature in Prader-Willi syndrome , 1986 .

[25]  R. Rogers,et al.  Oxytocin, oxytocin antagonist, TRH, and hypothalamic paraventricular nucleus stimulation effects on gastric motility , 1987, Peptides.